Biochemists and Professors at the University of North Texas Health Science Center and the Universities of Arizona and Kentucky, the Jacobsons have been researching and teaching for over 35 years. Dedicated to understanding niacin and niacin derived molecules in human health, much of their research and stringent clinical trials have been funded by the NIH. Their technology has been applied to the development of skincare, drugs for treatment and prevention of dermatology conditions and the prevention of cardiovascular diseases. One innovative, skin-repairing molecule was selected by the National Cancer Institute as a possible skin cancer prevention agent- NIA 114, and is now the foundation of all StriVectin products.
The Jacobsons have received numerous awards, amongst them: the Roger J. Williams Award in Preventive Nutrition (2005), the Outstanding University Achievement Award, University of Arizona (2007), the Kansas State University Alumni Fellows Award (2007), and the University of Arizona College of Pharmacy’s Findlay E. Russell Distinguished Citizen Award (2010) as joint recipients.
In 2011, the Jacobsons received the Innovators in Dermatology Award, along with StriVectin, from The Skin Cancer Foundation, which honors exceptional achievements in skin health.